Vascular Endothelial Growth Factor A (VEGFA) (Middle Region) Peptid
VEGFA
Reaktivität: Human
Wirt: Synthetic
BP, WB
Produktnummer ABIN5671953
150,78 €
Zzgl. Versandkosten 20,00 € und MwSt
100 μg
Lieferung nach:
Deutschland
Lieferung in 15 bis 21 Werktagen
Kurzübersicht für Vascular Endothelial Growth Factor A (VEGFA) (Middle Region) Peptid (ABIN5671953)
Target
VEGFA
(Vascular Endothelial Growth Factor A (VEGFA))
Spezies
Human
Quelle
Synthetic
Applikation
Blocking Peptide (BP), Western Blotting (WB)
-
-
Protein Region
- Middle Region
-
Sequenz
- QGQHIGEMSF LQHNKCECRP KKDRARQEKK SVRGKGKGQK RKRKKSRYKS
-
Produktmerkmale
- This is a synthetic peptide designed for use in combination with anti- VEGFA Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Rekonstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- VEGFA (Vascular Endothelial Growth Factor A (VEGFA))
-
Hintergrund
-
This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site.
Alias Symbols: VPF, VEGF, MVCD1
Protein Size: 412 -
Gen-ID
- 7422
-
NCBI Accession
- NM_001025366, NP_001020537
Target
-
Sie sind hier:
